BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220314
DTEND;VALUE=DATE:20220316
DTSTAMP:20260516T010132
CREATED:20211220T170251Z
LAST-MODIFIED:20211220T170251Z
UID:32612-1647216000-1647388799@www.pharmajournalist.com
SUMMARY:SMi’s 3rd Annual AI in Drug Discovery Conference
DESCRIPTION:SMi’s 3rd Annual AI in Drug Discovery Conference \nConference: 14 – 15 March 2022\nLondon\, UK\nWebsite: http://www.ai-indrugdiscovery.com/PJwl \nChaired by Darren Green\, Director of Computational Chemistry\, GSK \nSponsored by: Optibrium \nExploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare \nSMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference\, taking place on the 14th and 15th March 2022 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nAI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years\, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward. \nJoin us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI\, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field\, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery. \nEvent Hashtag: #SMiAIDrugDis \nKey Reasons to Attend: \n\nDiscover the main topics of research within industry\, with talks on decision making\, target selection and closing the loop\nEngage with regulators about the guidance within machine learning and AI in Drug Discovery\nLearn about the new breakthroughs within clinical trials and the treatment of disease\nExplore the latest technologies in deep learning from leaders within the pharmaceutical industry\nDiscuss the impact of big data and how it applies to AI drug discovery within Pharma\n\nWho Should Attend? \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-3rd-annual-ai-in-drug-discovery-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR